{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:01:50Z","timestamp":1793682110483,"version":"4.5.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is considerable heterogeneity in the rate of lung function decline in chronic obstructive pulmonary disease (COPD), the determinants of which are largely unknown. Observational studies in COPD indicate that low body mass index (BMI) is associated with worse outcomes, and overweight\/obesity has a protective effect \u2013 the so-called \u201cobesity paradox\u201d. We aimed to determine the relationship between BMI and the rate of FEV<jats:sub>1<\/jats:sub> decline in data from published clinical trials in COPD.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a systematic review of the literature, and identified 5 randomized controlled trials reporting the association between BMI and FEV<jats:sub>1<\/jats:sub> decline. Four of these were included in the meta-analyses. We analyzed BMI in 4 categories: BMI-I (&lt;\u200918.5 or\u2009&lt;\u2009\u00a020\u2009kg\/m<jats:sup>2<\/jats:sup>), BMI-II (18.5 or 20 to &lt;\u200925\u2009kg\/m<jats:sup>2<\/jats:sup>), BMI-III (25 to &lt;\u200929 or\u2009&lt;\u200930\u2009kg\/m<jats:sup>2<\/jats:sup>) and BMI-IV (\u226529 or\u2009\u2265\u200930\u2009kg\/m<jats:sup>2<\/jats:sup>). We then performed a meta-regression of all the estimates against the BMI category.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The estimated rate of FEV<jats:sub>1<\/jats:sub> decline decreased with increasing BMI. Meta-regression of the estimates showed that BMI was significantly associated with the rate of FEV<jats:sub>1<\/jats:sub> decline (linear trend <jats:italic>p<\/jats:italic>\u00a0=\u20091.21\u2009\u00d7\u200910<jats:sup>\u2212\u20095<\/jats:sup>).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These novel findings support the obesity paradox in COPD: compared to normal BMI, low BMI is a risk factor for accelerated lung function decline, whilst high BMI has a protective effect. The relationship may be due to common but as-of-yet unknown causative factors; further investigation into which may reveal novel endotypes or targets for therapeutic intervention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-019-1209-5","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T20:44:07Z","timestamp":1572468247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["BMI is associated with FEV1 decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials"],"prefix":"10.1186","volume":"20","author":[{"given":"Yilan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen Erh","family":"Jaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Xi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u2019en","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don D.","family":"Sin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"issue":"13","key":"1209_CR1","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa1105482","volume":"365","author":"J Vestbo","year":"2011","unstructured":"Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184\u201392.","journal-title":"N Engl J Med"},{"issue":"3","key":"1209_CR2","doi-asserted-by":"publisher","first-page":"1700214","DOI":"10.1183\/13993003.00214-2017","volume":"49","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214.","journal-title":"Eur Respir J"},{"issue":"5","key":"1209_CR3","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1183\/09031936.00128008","volume":"33","author":"PJ Barnes","year":"2009","unstructured":"Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165\u201385.","journal-title":"Eur Respir J"},{"issue":"6","key":"1209_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/thx.2007.086371","volume":"63","author":"E Crisafulli","year":"2008","unstructured":"Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax. 2008;63(6):487\u201392.","journal-title":"Thorax"},{"issue":"6","key":"1209_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1164\/ajrccm.160.6.9902115","volume":"160","author":"C Landbo","year":"1999","unstructured":"Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(6):1856\u201361.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1209_CR6","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1164\/ajrccm.157.6.9705017","volume":"157","author":"AMWJ Schols","year":"1998","unstructured":"Schols AMWJ, Slangen J, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(6):1791\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1209_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1471-2466-14-151","volume":"14","author":"W Hasegawa","year":"2014","unstructured":"Hasegawa W, Yamauchi Y, Yasunaga H, Sunohara M, Jo T, Matsui H, et al. Factors affecting mortality following emergency admission for chronic obstructive pulmonary disease. BMC Pulm Med. 2014;14:151.","journal-title":"BMC Pulm Med"},{"key":"1209_CR8","first-page":"571","volume":"7","author":"G Gudmundsson","year":"2012","unstructured":"Gudmundsson G, Ulrik CS, Gislason T, Lindberg E, Brondum E, Bakke P, et al. Long-term survival in patients hospitalized for chronic obstructive pulmonary disease: a prospective observational study in the Nordic countries. Int J Chron Obstruct Pulmon Dis. 2012;7:571\u20136.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1209_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.7326\/0003-4819-138-1-200301070-00008","volume":"138","author":"A Peeters","year":"2003","unstructured":"Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, Mamun AA, Bonneux L, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138(1):24\u201332.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1209_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0735-1097(01)01802-2","volume":"39","author":"L Gruberg","year":"2002","unstructured":"Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, Pinnow EE, et al. The impact of obesity on the short-term andlong-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol. 2002;39(4):578\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"1209_CR11","unstructured":"PROSPERO database [Available from: \n                    www.crd.york.ac.uk\/prospero\n                    \n                  . Accessed 24 May 2019."},{"key":"1209_CR12","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6(7).","DOI":"10.1371\/journal.pmed.1000100"},{"key":"1209_CR13","unstructured":"Higgins J, Green Se. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from \n                    http:\/\/handbook.cochrane.org\n                    \n                  . 2011. Accessed 24 May 2019."},{"issue":"7109","key":"1209_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"6","key":"1209_CR15","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.jaci.2016.04.022","volume":"138","author":"R Tkacova","year":"2016","unstructured":"Tkacova R, Dai DLY, Vonk JM, Leung JM, Hiemstra PS, van den Berge M, et al. Airway hyperresponsiveness in chronic obstructive pulmonary disease: a marker of asthma-chronic obstructive pulmonary disease overlap syndrome? J Allergy Clin Immunol. 2016;138(6):1571\u20139 e1510.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1209_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","volume":"178","author":"BR Celli","year":"2008","unstructured":"Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1209_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1164\/rccm.201610-2086OC","volume":"197","author":"PMA Calverley","year":"2018","unstructured":"Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, et al. Fluticasone furoate, vilanterol, and lung function decline in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. Am J Respir Crit Care Med. 2018;197(1):47\u201355.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10030","key":"1209_CR18","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","volume":"387","author":"J Vestbo","year":"2016","unstructured":"Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817\u201326.","journal-title":"Lancet"},{"issue":"15","key":"1209_CR19","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543\u201354.","journal-title":"N Engl J Med"},{"key":"1209_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12931-015-0269-4","volume":"16","author":"A Anzueto","year":"2015","unstructured":"Anzueto A, Wise R, Calverley P, Dusser D, Tang W, Metzdorf N, et al. The Tiotropium safety and performance in Respimat(R) (TIOSPIR(R)) trial: spirometry outcomes. Respir Res. 2015;16:107.","journal-title":"Respir Res"},{"issue":"8","key":"1209_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ppul.23217","volume":"50","author":"J Cogen","year":"2015","unstructured":"Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, et al. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol. 2015;50(8):763\u201370.","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"1209_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1378\/chest.121.2.370","volume":"121","author":"RI Harik-Khan","year":"2002","unstructured":"Harik-Khan RI, Fleg JL, Wise RA. Body mass index and the risk of COPD. Chest. 2002;121(2):370\u20136.","journal-title":"Chest"},{"key":"1209_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.rmed.2016.02.003","volume":"113","author":"MC Mirabelli","year":"2016","unstructured":"Mirabelli MC, Preisser JS, Loehr LR, Agarwal SK, Barr RG, Couper DJ, et al. Lung function decline over 25 years of follow-up among black and white adults in the ARIC study cohort. Respir Med. 2016;113:57\u201364.","journal-title":"Respir Med"},{"issue":"5","key":"1209_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2012.39","volume":"307","author":"KM Flegal","year":"2012","unstructured":"Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491\u20137.","journal-title":"JAMA"},{"issue":"1","key":"1209_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.chest.2016.08.1432","volume":"151","author":"AA Lambert","year":"2017","unstructured":"Lambert AA, Putcha N, Drummond MB, Boriek AM, Hanania NA, Kim V, et al. Obesity is associated with increased morbidity in moderate to severe COPD. Chest. 2017;151(1):68\u201377.","journal-title":"Chest"},{"issue":"7","key":"1209_CR26","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/oby.2004.131","volume":"12","author":"J Bigaard","year":"2004","unstructured":"Bigaard J, Frederiksen K, Tj\u00f8nneland A, Thomsen BL, Overvad K, Heitmann BL, et al. Body fat and fat-free mass and all-cause mortality. Obes Res. 2004;12(7):1042\u20139.","journal-title":"Obes Res"},{"key":"1209_CR27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/sj.ijo.0802976","volume":"29","author":"J Bigaard","year":"2005","unstructured":"Bigaard J, Frederiksen K, Tj\u00f8nneland A, Thomsen BL, Overvad K, Heitmann BL, et al. Waist circumference and body composition in relation to all-cause mortality in middle-aged men and women. Int J Obes. 2005;29:778.","journal-title":"Int J Obes"},{"issue":"1","key":"1209_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ajcn\/82.1.53","volume":"82","author":"AM Schols","year":"2005","unstructured":"Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53\u20139.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"1209_CR29","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1183\/09031936.00111707","volume":"31","author":"J Vestbo","year":"2008","unstructured":"Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869\u201373.","journal-title":"Eur Respir J"},{"issue":"1","key":"1209_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1378\/chest.06-2789","volume":"132","author":"E Ischaki","year":"2007","unstructured":"Ischaki E, Papatheodorou G, Gaki E, Papa I, Koulouris N, Loukides S. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest. 2007;132(1):164\u20139.","journal-title":"Chest"},{"key":"1209_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/sj.ejcn.1602708","volume":"62","author":"S Budweiser","year":"2007","unstructured":"Budweiser S, Meyer K, J\u00f6rres RA, Heinemann F, Wild PJ, Pfeifer M. Nutritional depletion and its relationship to respiratory impairment in patients with chronic respiratory failure due to COPD or restrictive thoracic diseases. Eur J Clin Nutr. 2007;62:436.","journal-title":"Eur J Clin Nutr"},{"issue":"11","key":"1209_CR32","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.rmed.2006.03.008","volume":"100","author":"G Sergi","year":"2006","unstructured":"Sergi G, Coin A, Marin S, Vianello A, Manzan A, Peruzza S, et al. Body composition and resting energy expenditure in elderly male patients with chronic obstructive pulmonary disease. Respir Med. 2006;100(11):1918\u201324.","journal-title":"Respir Med"},{"issue":"3","key":"1209_CR33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1183\/09031936.00074807","volume":"31","author":"PD Wagner","year":"2008","unstructured":"Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 2008;31(3):492\u2013501.","journal-title":"Eur Respir J"},{"issue":"4","key":"1209_CR34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1164\/rccm.2108013","volume":"166","author":"AG Agusti","year":"2002","unstructured":"Agusti AG, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(4):485\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1209_CR35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1183\/09031936.03.00405703","volume":"21","author":"AGN Agusti","year":"2003","unstructured":"Agusti AGN, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(2):347\u201360.","journal-title":"Eur Respir J"},{"issue":"3","key":"1209_CR36","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1183\/09031936.02.01282001","volume":"20","author":"M Bottai","year":"2002","unstructured":"Bottai M, Pistelli F, Di Pede F, Carrozzi L, Baldacci S, Matteelli G, et al. Longitudinal changes of body mass index, spirometry and diffusion in a general population. Eur Respir J. 2002;20(3):665\u201373.","journal-title":"Eur Respir J"},{"issue":"4","key":"1209_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1136\/thx.48.4.375","volume":"48","author":"Y Chen","year":"1993","unstructured":"Chen Y, Horne SL, Dosman JA. Body weight and weight gain related to pulmonary function decline in adults: a six year follow up study. Thorax. 1993;48(4):375\u201380.","journal-title":"Thorax"},{"issue":"7","key":"1209_CR38","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1164\/rccm.200405-651OC","volume":"170","author":"HO Coxson","year":"2004","unstructured":"Coxson HO, Chan IHT, Mayo JR, Hlynsky J, Nakano Y, Birmingham CL. Early emphysema in patients with anorexia nervosa. Am J Respir Crit Care Med. 2004;170(7):748\u201352.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1209_CR39","first-page":"619","volume":"124","author":"H Sahebjami","year":"1981","unstructured":"Sahebjami H, Wirman JA. Emphysema-like changes in the lungs of starved rats. Am Rev Respir Dis. 1981;124(5):619\u201324.","journal-title":"Am Rev Respir Dis"},{"issue":"2 Pt 2","key":"1209_CR40","doi-asserted-by":"publisher","first-page":"R282","DOI":"10.1152\/ajpregu.1986.251.2.R282","volume":"251","author":"JB Karlinsky","year":"1986","unstructured":"Karlinsky JB, Goldstein RH, Ojserkis B, Snider GL. Lung mechanics and connective tissue levels in starvation-induced emphysema in hamsters. Am J Physiol Regul Integr Comp Physiol. 1986;251(2 Pt 2):R282\u20138.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"1209_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1165\/rcmb.2010-0294OC","volume":"45","author":"ES Wan","year":"2011","unstructured":"Wan ES, Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, et al. Genome-wide association analysis of body mass in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2011;45(2):304\u201310.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"1209_CR42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1164\/rccm.200607-896OC","volume":"175","author":"J Garcia-Aymerich","year":"2007","unstructured":"Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Ant\u00f3 JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(5):458\u201363.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1209_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2466-9-26","volume":"9","author":"D Stav","year":"2009","unstructured":"Stav D, Raz M, Shpirer I. Three years of pulmonary rehabilitation: inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease. BMC Pulm Med. 2009;9(1):26.","journal-title":"BMC Pulm Med"},{"issue":"7","key":"1209_CR44","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1210\/jc.2002-021687","volume":"88","author":"G van Hall","year":"2003","unstructured":"van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003;88(7):3005\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1209_CR45","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1152\/japplphysiol.01026.2004","volume":"98","author":"F Haddad","year":"2005","unstructured":"Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl Physiol. 2005;98(3):911\u20137.","journal-title":"J Appl Physiol"},{"key":"1209_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nm0102-75","volume":"8","author":"V Wallenius","year":"2002","unstructured":"Wallenius V, Wallenius K, Ahr\u00e9n B, Rudling M, Carlsten H, Dickson SL, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8:75.","journal-title":"Nat Med"},{"issue":"1","key":"1209_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12931-014-0103-4","volume":"15","author":"AK Ravi","year":"2014","unstructured":"Ravi AK, Khurana S, Lemon J, Plumb J, Booth G, Healy L, et al. Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. Respir Res. 2014;15(1):103.","journal-title":"Respir Res"},{"issue":"1","key":"1209_CR48","first-page":"20","volume":"76","author":"E Girardin","year":"1992","unstructured":"Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer JM. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 study group. Immunology. 1992;76(1):20\u20133.","journal-title":"Immunology"},{"issue":"6","key":"1209_CR49","doi-asserted-by":"publisher","first-page":"L1035","DOI":"10.1152\/ajplung.00397.2007","volume":"294","author":"R Summer","year":"2008","unstructured":"Summer R, Little FF, Ouchi N, Takemura Y, Aprahamian T, Dwyer D, et al. Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. Am J Physiol Lung Cell Mol Physiol. 2008;294(6):L1035\u201342.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"1209_CR50","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1378\/chest.11-2173","volume":"142","author":"HI Yoon","year":"2012","unstructured":"Yoon HI, Li Y, Man SFP, Tashkin D, Wise RA, Connett JE, et al. The complex relationship of serum adiponectin to COPD outcomes. Chest. 2012;142(4):893\u20139.","journal-title":"Chest"},{"issue":"1","key":"1209_CR51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nri1528","volume":"5","author":"JR Wright","year":"2005","unstructured":"Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. 2005;5(1):58\u201368.","journal-title":"Nat Rev Immunol"},{"key":"1209_CR52","doi-asserted-by":"crossref","unstructured":"Obeidat M, Li X, Burgess S, Zhou G, Fishbane N, Hansel NN, et al. Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation. Eur Respir J. 2017;50(5):1700657.","DOI":"10.1183\/13993003.00657-2017"},{"key":"1209_CR53","doi-asserted-by":"crossref","unstructured":"Sorensen GL, Hjelmborg JvB, Leth-Larsen R, Schmidt V, Fenger M, Poulain F, et al. Surfactant protein D of the innate immune defence is inversely associated with human obesity and SP-D deficiency infers increased body weight in mice. Scand J Immunol. 2006;64(6):633\u20138.","DOI":"10.1111\/j.1365-3083.2006.01853.x"},{"issue":"10","key":"1209_CR54","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/cvr\/cvx067","volume":"113","author":"Y Hirano","year":"2017","unstructured":"Hirano Y, Choi A, Tsuruta M, Jaw JE, Oh Y, Ngan D, et al. Surfactant protein-D deficiency suppresses systemic inflammation and reduces atherosclerosis in ApoE knockout mice. Cardiovasc Res. 2017;113(10):1208\u201318.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"1209_CR55","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1073\/pnas.100448997","volume":"97","author":"SE Wert","year":"2000","unstructured":"Wert SE, Yoshida M, LeVine AM, Ikegami M, Jones T, Ross GF, et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci U S A. 2000;97(11):5972\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1209_CR56","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2147\/COPD.S138571","volume":"12","author":"Y-F Wei","year":"2017","unstructured":"Wei Y-F, Tsai Y-H, Wang C-C, Kuo P-H. Impact of overweight and obesity on acute exacerbations of COPD - subgroup analysis of the Taiwan obstructive lung disease cohort. Int J Chron Obstruct Pulmon Dis. 2017;12:2723\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1209-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-1209-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1209-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:27:41Z","timestamp":1603844861000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-1209-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-1209-5","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,29]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SM reports personal fees from Novartis, Boehringer Ingelheim and Menarini, and non-financial support from Draeger Australia, outside the submitted work. DDS reports grants from Merck, personal fees from Sanofi-Aventis, Regeneron and Novartis, and grants and personal fees from Boehringer Ingelheim and AstraZeneca, outside the submitted work. YS, JEJ, CXY, FX, XL, and MO have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}